Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

9.500 -0.330 (-3.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Vir Biotechnology Earnings Perspective: Return On Capital Employed ↗
According to Benzinga Pro, during Q2, Vir Biotechnology (NASDAQ:VIR) earned $61.02 million, a 138.46% increase from the preceding quarter. Vir Biotechnology also posted a total of... 
Via Benzinga
News headline image
Now May Be the Big Moment for These 2 COVID Stocks ↗
Their products are seeing a surge in demand. 
Via The Motley Fool
News headline image
9 Health Care Stocks With Unusual Options Alerts In Today's Session ↗
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
News headline image
Vir Biotech-GSK's COVID-19 Treatment Wins Provisional Approval In Australia ↗
The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's (NASDAQ: VIR) for sotrovimab,... 
Via Benzinga
News headline image
3 Vaccine Stocks for the Next Decade ↗
Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years? 
Via The Motley Fool
Unusual Options Activity Insight: Vir Biotechnology ↗
Shares of Vir Biotechnology (NASDAQ:VIR) saw some unusual ... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2021 ↗
Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million. •... 
Via Benzinga
News headline image
European Commission To Procure 220K Doses Of Glaxo-Vir Biotech's COVID-19 Antibody ↗
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of... 
Via Benzinga
News headline image
Vir Biotechnology Starts Dosing In Mid-Stage Hepatitis B Trial With Combination Therapy ↗
Vir Biotechnology Inc (NASDAQ: VIR) has dosed the first patient in the Phase 2 MARCH trial evaluating VIR-2218 in combination with VIR-3434 to treat patients with... 
Via Benzinga
News headline image
GlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know ↗
The sample size was small, but the results were impressive. 
Via The Motley Fool
News headline image
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters ↗
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial... 
Via Benzinga
News headline image
Vir Biotech's HBV Candidates Show Positive Safety Profiles ↗
Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Osmotica Pharmaceuticals (NASDAQ:OSMT) stock increased by 39.78% to $3.97 during Friday's regular session. The current volume of 48.4 million shares is 18988.... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
News headline image
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters ↗
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
News headline image
GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients ↗
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating... 
Via Benzinga
News headline image
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
News headline image
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
News headline image
15 Words From Vir Biotechnology's CEO May Mean Market Dominance ↗
Vir's antibody treatment is addressing one of the biggest COVID challenges. 
Via The Motley Fool
News headline image
The Surprising Move Vir Stock Made After Winning Covid Drug Authorization ↗
GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
News headline image
Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug ↗
The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and ... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers Zosano Pharma (NASDAQ:ZSAN) stock moved upwards by 22.59% to $0.91 during Thursday's pre-market session. The company's market cap stands at $97.3 million.... 
Via Benzinga
News headline image
24 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) rose 82% to $3.24 in pre-market trading after the company announced plans to acquire a Alabama refinery and related logistics assets.... 
Via Benzinga
News headline image
Market Briefing For Thursday, May 27 ↗
Dynamics spurring last year's upside, mostly sputtered with sector-rotation since early February. Periodically breadth broadens out slightly and a move in unison occurs, absent sustainability. 
Via Talk Markets
News headline image
GlaxoSmithKline - Vir Biotech's Antibody COVID-19 Treatment Wins CHMP's Positive Scientific Opinion ↗
The European Medicines Agency’s advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Vir Biotechnology (NASDAQ:VIR) sha... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.